The impact on survival of CPT-11 as third-line or later treatment in advanced gastric cancer

被引：0
|
作者：
Makiyama, A. [1 ]
Arimizu, K. [1 ]
Hirano, G. [1 ]
Makiyama, C. [1 ]
Matsushita, Y. [2 ]
Shirakawa, T. [3 ]
Ohmura, H. [4 ]
Komoda, M. [4 ]
Uchino, K. [4 ]
Inadomi, K. [5 ]
Kusaba, H. [6 ]
Shinohara, Y. [7 ]
Kuwayama, M. [7 ]
Kajitani, T. [7 ]
Esaki, T. [8 ]
Baba, E. [9 ]
机构：
[1] Japan Community Healthcare Org Kyushu Hosp, Dept Hematol Oncol, Kitakyushu, Fukuoka, Japan
[2] Hamanomachi Hosp, Dept Med Oncol, Fukuoka, Japan
[3] Miyazaki Prefectural Miyazaki Hosp, Miyazaki, Japan
[4] Natl Hosp Org Kyushu Med Ctr, Dept Med Oncol, Fukuoka, Japan
[5] Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Fukuoka, Japan
[6] Kyushu Univ, Dept Med & Biosyst Sci, Fukuoka, Japan
[7] Kyushu Natl Canc Ctr, Fukuoka, Japan
[8] Kyushu Natl Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Japan
[9] Kyushu Univ, Dept Comprehens Clin Oncol, Fac Med Sci, Fukuoka, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-171
引用
收藏
页码：51 / 51
页数：1
相关论文
共 50 条
  • [21] Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer - Discussion
    Velanovich, V
    Newman, E
    Kelly, K
    Zenilman, M
    Fink, V
    Pellegrini, C
    JOURNAL OF GASTROINTESTINAL SURGERY, 2002, 6 (02) : 223 - 223
  • [22] Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes
    Nishimura, Takashi
    Iwasa, Satoru
    Nagashima, Kengo
    Okita, Natsuko
    Takashima, Atsuo
    Honma, Yoshitaka
    Kato, Ken
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Shimada, Yasuhiro
    Boku, Narikazu
    GASTRIC CANCER, 2017, 20 (04) : 655 - 662
  • [23] Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer
    Ishii, Takahiro
    Kawazoe, Akihito
    Sasaki, Akinori
    Mishima, Saori
    Kentaro, Sawada
    Nakamura, Yoshiaki
    Kotani, Daisuke
    Kuboki, Yasutoshi
    Taniguchi, Hiroya
    Kojima, Takashi
    Doi, Toshihiko
    Yoshino, Takayuki
    Kuwata, Takeshi
    Ishii, Genichiro
    Shitara, Kohei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [24] Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes
    Takashi Nishimura
    Satoru Iwasa
    Kengo Nagashima
    Natsuko Okita
    Atsuo Takashima
    Yoshitaka Honma
    Ken Kato
    Tetsuya Hamaguchi
    Yasuhide Yamada
    Yasuhiro Shimada
    Narikazu Boku
    Gastric Cancer, 2017, 20 : 655 - 662
  • [25] Factors of the third-line treatment induction in advanced gastric cancer based on eligibility for clinical trials
    Sakumura, Miho
    Ando, Takayuki
    Hirano, Katsuhisa
    Miwa, Takeshi
    Motoo, Iori
    Kajiura, Shinya
    Ueda, Yuko
    Ogawa, Kohei
    Tsukada, Kenichiro
    Ueda, Akira
    Nakada, Naokatsu
    Hosokawa, Ayumu
    Fujii, Tsutomu
    Yasuda, Ichiro
    ANNALS OF ONCOLOGY, 2022, 33 : S534 - S534
  • [26] IRINOTECAN AS A THIRD-LINE TREATMENT OF ADVANCED GASTRIC CANCER AFTER FAILURE OF FLUOROPYRIMIDINE, PLATINUM, AND TAXANES
    Nishimura, Takashi
    Iwasa, Satoru
    Shoji, Hirokazu
    Okita, Natsuko
    Takashima, Atsuo
    Honma, Yoshitaka
    Kato, Ken
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Shimada, Yasuhiro
    ANNALS OF ONCOLOGY, 2014, 25
  • [27] Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer
    Quintela-Fandino, M
    Gravalos, C
    Gonzalez, E
    Garcia-Velasco, A
    Cortés-Funes, H
    ANTI-CANCER DRUGS, 2005, 16 (01) : 31 - 38
  • [28] Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer
    Katsube, Takao
    Ogawa, Kenji
    Ichikawa, Wataru
    Fujii, Masashi
    Tokunaga, Akira
    Takagi, Yuh
    Kochi, Misugu
    Hayashi, Kazuhiko
    Kubota, Tetsuro
    Aiba, Keisuke
    Arai, Kuniyoshi
    Terashima, Masanori
    Kitajima, Masaki
    ANTI-CANCER DRUGS, 2007, 18 (05) : 605 - 610
  • [29] Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer
    Sugiyama, T
    Yakushiji, M
    Kamura, T
    Ikeda, M
    Umesaki, N
    Hasegawa, K
    Ishikawa, M
    Saji, F
    Hiura, M
    Takahashi, T
    Sato, S
    Ochiai, K
    Kikkawa, F
    Takeuchi, S
    Ohashi, Y
    Noda, K
    ONCOLOGY, 2002, 63 (01) : 16 - 22
  • [30] A budget impact model of third-line or later trifluridine/tipiracil treatment of metastatic colorectal cancer.
    Ferrufino, Cheryl
    Wiseman, Fred
    Wert, Tim D.
    Barghout, Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345